Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Charles Edelstein to Sirolimus

This is a "connection" page, showing publications Charles Edelstein has written about Sirolimus.

 
Connection Strength
 
 
 
2.180
 
  1. Holditch SJ, Brown CN, Atwood DJ, Lombardi AM, Nguyen KN, Toll HW, Hopp K, Edelstein CL. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol. 2019 07 01; 317(1):F187-F196.
    View in: PubMed
    Score: 0.520
  2. Davis S, Gralla J, Chan L, Wiseman A, Edelstein CL. Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study. Transplant Proc. 2018 Jun; 50(5):1243-1248.
    View in: PubMed
    Score: 0.488
  3. Belibi F, Ravichandran K, Zafar I, He Z, Edelstein CL. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease. Am J Physiol Renal Physiol. 2011 Jan; 300(1):F236-44.
    View in: PubMed
    Score: 0.287
  4. Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int. 2010 Oct; 78(8):754-61.
    View in: PubMed
    Score: 0.284
  5. Zafar I, Belibi FA, He Z, Edelstein CL. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant. 2009 Aug; 24(8):2349-53.
    View in: PubMed
    Score: 0.258
  6. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol. 2005 Jan; 16(1):46-51.
    View in: PubMed
    Score: 0.191
  7. Ravichandran K, Zafar I, He Z, Doctor RB, Moldovan R, Mullick AE, Edelstein CL. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2. Hum Mol Genet. 2014 Sep 15; 23(18):4919-31.
    View in: PubMed
    Score: 0.092
  8. Edelstein CL. Therapeutic interventions for autosomal dominant polycystic kidney disease. Nephrol News Issues. 2008 Mar; 22(3):25-6.
    View in: PubMed
    Score: 0.060
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)